(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s website showed on Friday.
The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely.
Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.